NEW YORK (TheStreet) -- Amicus Therapeutics  (FOLD) surged Tuesday after the company announced its lead drug migalastat was effective in treating patients with Fabry disease in a late-stage trial.

Amicus found the drug effective in patients after 12 months of treatment in the trial, which tested migalastat as a form of monotherapy in patients with Fabry disease, a disorder in which a fat called globotriaosylceramide builds up in the body's cells. The company also released positive 24-month data. 

"Today is a great day for Amicus and the Fabry community," said Chairman and CEO John F. Crowley in a statement. "Pending positive data from our second Phase 3 study we expect to meet with regulatory authorities to discuss these data and determine the fastest registration pathway for migalastat."

Must Read: Warren Buffett's 10 Favorite Growth Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was up 21.74% to $2.24 at 2:04 p.m.

FOLD Chart

FOLD data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

BuzzFeed to Lay Off 15% of Staff: Reports

BuzzFeed to Lay Off 15% of Staff: Reports

Market Movers: January FOMC Meeting

Market Movers: January FOMC Meeting

3 Things to Know at Market Close: 2019 IPO's, IBM Earnings, and Oil

3 Things to Know at Market Close: 2019 IPO's, IBM Earnings, and Oil

Texas Instruments Rises After Beating Earnings Estimates, Missing Guidance

Texas Instruments Rises After Beating Earnings Estimates, Missing Guidance

Dell Shares Up Amid Optimism Over Debt Pay-Down

Dell Shares Up Amid Optimism Over Debt Pay-Down